Active Ingredient(s): Deutetrabenazine
FDA Approved: * April 3, 2017
Pharm Company: * TEVA PHARMS USA INC
Category: Neurological Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Austedo Overview

Deutetrabenazine (trade name Austedo) is a pharmaceutical drug for the treatment of chorea associated with Huntington’s disease.[1] Chemically, deutetrabenazine is an analog of tetrabenazine in which six hydrogen atoms have been replaced by deuterium atoms. The incorporation of deuterium slows the rate of drug metabolism, allowing less frequent dosing.[2][3] References ^ "FDA Approves Drug for Huntington's Disease". April 3, 2017. ^ Citrome L (April 2016). "Breakthrough Drugs for th...

Read more Austedo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Austedo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 12mg, 6mg, 9mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Austedo: (3 results)

Sorted by National Drug Code
  • 68546-170 Austedo 6 mg Oral Tablet, Coated by Teva Neuroscience, Inc.
  • 68546-171 Austedo 9 mg Oral Tablet, Coated by Teva Neuroscience, Inc.
  • 68546-172 Austedo 12 mg Oral Tablet, Coated by Teva Neuroscience, Inc.

Other drugs which contain Deutetrabenazine or a similar ingredient: (1 result)